Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HYBE .0016 falling now!!! Slow and steady all the way up!!! Get your tickets!!! Next runner is HERE!! BIDS building!!! Pushing this one north!!! Look at chart!! Breakout!!!
$HYBE Breaking out!! Blue sky runner coming today!! No shares on L2!!
$HYBE .0015!!! 5 day chart is amazing!!! triple 0 runner!!! bids building !!! Price isnt done climbing yet!!
15 up!! .002 coming!! $HYBE!!
$HYBE .0014 !! Look at 5 day chart on this one!!! accumulation at its highest point!! Breakout day today!!
$HYBE .0014 Day 4 !! Lots of Profit making going on here and no real drop in price!! High yesterday was .0016!! Lets hit .002 today!! ! New round of buying starts today!!
Power Hour coming thru with the late day push!! Close of .0015-16 would be ideal... but anything green sets up the Three White Soldiers chart formation!
RSI has reset... but Accumulation is still goin up!! this run isnt over yet!! Chart right on Moving average !! Id expect a move north right into the close!!
$HYBE Support @ .001 and .0012 .. Lunch time dip!! Next push to break resistance at .0017 ... Then .002 + Volume after lunch will be the deciding factor!
Lots of people that bought low took their profits , some still riding the wave!! New buyers coming in to replace them!! Accumulation on the charts looks awesome!!
$HYBE .0015 NOW!!!! 5 day chart is stunning!!! No slowing down this train!! Slow and steady till .01!
You were saying this about BRTX* also..... you crazy man... I hope you got shares in that one.... sitting below .001 last week... now about to pass .01
Your post are my rewards! thanks!
$HYBE Hope ppl are watching this action!! .002 very possible today!!!
Seeing the bid jumps.... ask doing nothing!! Bids getting bigger!!! .0015 in minutes!!!
Im buying on momentum and volume / selling on any news...
So many of these stocks run on nothing... then do nothing when news actually comes up!!
MMs are putting stacks on the bid once the selling stops to drive up the price... This run isnt over yet!!
Sellers will be sorry by end of day!! big bid will come in and push this north!! they will glady take your shares at this price!! $HYBE
$GEVO off to the races!!
15 mil bid @ .001 7 mil shares @ .0012 ... bout to be nothing @ .0011
Shares exchanging hands from weak ones to strong ones!! stair stepping, next leg is .0015-.002
$HYBE .0012 Day 3 of Breakout Starting soon!! Posted it here thursday, Price was .0003
Premarket moving!!! .0013/ .0014 right now!! Breakout coming!
I follow him just to buy into the stocks he says are scams.... Look at his history.... all those stocks have been doing good lately!! LOL Sounds like we got another green day here!!
It wasnt a one day fluke.... started w/ 100 mil + first day.... 300 mil + friday! Breakout day 3 ! Starting soon $HYBE .0012
$HYBE .0013 up 160% going into weekend!! Grab those shares now!! 2 day runner so far!! Monday gapper then wave 3!!
$HYBE whoever got in early today !! .0005 / .0006 Congrats!!! Sitting at .0013 now looking to finish strong going into weekend!! Missing out on big profit waiting on news.....
$HYBE No more shares @ .0011 12s falling!! Gonna be a heater going into the weekend!! Hype will spread!!
Retrace to .001.. Round 2 coming fast and even thinner this time!! .002 by End of Day?
$HYBE .0006 a milly left @ 6.... 20 mil @ .0007 Nothing for a penny stock!! Trips will be gone today!!! DAy 2 of breakout!! get in!! Huge Runner!!
$HYBE .0006 Big bids pushing this north!!! .001 coming today!!! L2 thin!! few mil @ .0006
$HYBE .0006 Big bidders keep popping up!!! Moving it more north!! .001 coming!!
HYBE SHMN 2 triple 0 stocks you should own!!!
$HYBE hope yall got in at 4 yesterday!!! Ask up to .0007....
RLFTF # 1 on Breakout!!! Covid Cure!!
Volume exploded yesterday once markets opened.... so whats gonna happen today? same thing?
but I picked up 2k more at 1.30... Lets double it at least!!
pretty crappy tho when in afterhours it was 2.07 at close!! open at 1.50 after all those buys above that price.... 990 mil volume!! WE keep getting volume... I think 5$ is possible !! We'll see I guess...
GEVO then!! almost 1 bil shares traded!! NYSE @ 1.80
RLFTF (OTC) but Covid 19 cure play.... gonna be beast soon!!
$HYBE .0005 not many left!!!! Huge movenment today!!! get in before the gapper tomorrow... Shares will be gone within a few buys!!! L2 Super THIN!
in both!! few milly here.... 40k on gevo
$HYBE Setting up for an even bigger breakout tomorrow!!! .0005 19 mil shares @ 5... L2 THIN!!!!
..tooo late.... .0005 up and not many of them!!! This is your chance.... get in before tomorrow!!!
$HYBE .0004 will be gone by end of day!!! Breakout runner!!! get in soon!!!
$HYBE Triple 0 stock ready to breakout!!! few mil left @ .0004!! GONNA RUN!!!
$OPTI $RLFTF $NHMD $HYBE $SHMN All Bout to have an upswing!!! Gotta get in the right ones!!!! Smart Money makes money!!!
Sponsor:
NeuroRx, Inc.
Information provided by (Responsible Party):
NeuroRx, Inc.
Study DetailsTabular ViewNo Results PostedDisclaimerHow to Read a Study Record
Study Description
Go to sections
Brief Summary:
Brief Summary:
SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or mechanical ventilation. Mortality rates as high as 80% have been reported among those who require mechanical ventilation, despite best available intensive care.
Patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 (aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 µg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer.
The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFa IL-6 and other cytokines.
Condition or disease Intervention/treatment Phase
SARS-CoV 2
COVID
ARDS
ALI
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Dyspnea
Drug: RLF-100 (aviptadil)
Drug: Placebo
Device: Nebulized administration of RLF-100 or Placebo
Phase 2
Phase 3
Detailed Description:
Detailed Description:
Attack of the Alveolar Type II (ATII) cell via its ACE2 surface receptor by the SARS-CoV-2 virus leads to respiratory failure, morbidity, and frequently mortality in COVID-19. There is no approved treatment that specifically targets the pulmonary injury. Vasoactive Intestinal Peptide (VIP) is known to target the VPAC1 receptor of the ATII cell and to protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies. Aviptadil, a synthetic form of Vasoactive Intestinal Polypeptide (VIP) has been awarded FDA Orphan Drug Designation for the treatment of ARDS and Pulmonary Hypertension and EMEA Orphan Drug Designation for the treatment of ARDS and Sarcoid. RLF-100 (Aviptadil) has been granted FDA Fast Track Designation for the treatment of ARDS/Acute Lung Injury in COVID-19.
The objective of this study is to identify patients with moderate and severe COVID-19 who have not yet developed respiratory failure and to treat them with inhaled Vasoactive Intestinal Polypeptide (VIP) in the hope of preventing progression to Critical COVID-19 with Respiratory Failure.
Nonclinical studies demonstrate that VIP is 70% concentrated in the lung, where it binds primarily to ATII cells. VIP prevents NMDA-induced caspase-3 activation in the lung, inhibits IL6 and TNFa production, protects against HCl-induced pulmonary edema, These and other effects have been observed in numerous animal model systems of lung injury in mice, rats, guinea pigs, sheep, swine, and dogs. In these models, Aviptadil restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure.
Both intravenous and inhalation preclinical toxicology and safety pharmacology have been performed in four species, with a six month trial of inhaled RLF-100 in primates.
Aviptadil is approved for human use in Europe and has a demonstrated 20 year history of safety in numerous trials for Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and a phase I trial in ARDS. In that phase I trial, 8 patients with severe ARDS on mechanical ventilation were treated with ascending doses of VIP. Seven of the 8 patients were successfully extubated and were alive at the five day timepoint. Six left the hospital and one died of an unrelated cardiac event.
Five GCP phase 2 trials of RLF-100 have been conducted under European regulatory authority. Non GCP healthy volunteer studies have shown that i.v. infusion of Aviptadil is well tolerated with few adverse effects including alterations in blood pressure, heart rate, or ECG. In addition to published studies of human use, Aviptadil has been used on a compounded basis in certain ICUs for many years in the belief that it preserves life and restores function in pulmonary hypertension, ARDS, and Acute Lung Injury (ALI).
In this study, patients patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 100 µg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer.
The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFa IL-6 and other cytokines.
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 288 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter Randomized Placebo-controlled Trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Only the study pharmacist will be aware of treatment assignment
Primary Purpose: Treatment
Official Title: Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19
Estimated Study Start Date : July 1, 2020
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : November 30, 2020